JB
ADCT icon

Julian Baker’s ADC Therapeutics ADCT Stock Holding History

Julian Baker’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,418,107
Closed -$34.5M – 123
2021
Q2 		$34.5M Hold
1,418,107
– – 0.15% 50
2021
Q1 		$34.6M Hold
1,418,107
– – 0.15% 53
2020
Q4 		$45.4M Sell
1,418,107
-269,393
-16% -$8.83M 0.17% 36
2020
Q3 		$55.7M Hold
1,687,500
– – 0.22% 28
2020
Q2 		$79M Buy
+1,687,500
New +$64M 0.35% 24

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Julian Baker's ADCT Position: Q3 2021 in Review

Julian Baker sold out of ADC Therapeutics (ADCT) in Q3 2021, closing a stake of 1,418,107 shares — an estimated $34.5M sold.

Julian Baker first reported a position in ADCT in Q2 2020 and held it in 5 quarters. The position peaked at $79M in Q2 2020. 53 funds tracked by Wall St. Rank hold ADCT as of Q3 2021.

  • Julian Baker reported no remaining ADC Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Julian Baker sold 1,418,107 ADC Therapeutics shares in Q3 2021, an estimated $34.5M.
  • Julian Baker first reported a position in ADC Therapeutics in Q2 2020 and held it in 5 quarters.
  • Julian Baker's ADC Therapeutics position peaked at $79M in Q2 2020.
  • 53 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2021.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.